Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.32 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1485038 | 1.00 | HTR6 (0.50) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL1485035 | 1.00 | HTR6 (0.50) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL38659074 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Ammonia Solution, Strong SCHEMBL19410112 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL2200285 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL2200278 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| Bromide SCHEMBL1307460 | 0.98 | HTR6 (0.48) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL31209302 | 0.92 | HTR6 (0.53) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22527614 | 0.92 | HTR6 (0.53) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18123339 | 0.88 | HTR6 (0.57) | HTR6SMN1; SMN2PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | HTR6 1309/4885SMN1; SMN2 2884/4885PIK3CD 2136/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | HTR6 1239/4885SMN1; SMN2 4326/4885PIK3CD 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.